Huang CFA - China Pharma BOD Manager
| CPHI Stock | USD 0.19 0.01 5.00% |
Executive
Huang CFA is BOD Manager of China Pharma Holdings
| Address | No. 17, Jinpan Road, Haikou, China, 570216 |
| Phone | 86 89 8668 11730 |
| Web | https://www.chinapharmaholdings.com |
China Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1754) % which means that it has lost $0.1754 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7489) %, meaning that it created substantial loss on money invested by shareholders. China Pharma's management efficiency ratios could be used to measure how well China Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.24. The China Pharma's current Return On Capital Employed is estimated to increase to -0.27. As of now, China Pharma's Intangible Assets are increasing as compared to previous years. The China Pharma's current Intangibles To Total Assets is estimated to increase to 0.21, while Total Assets are projected to decrease to under 15.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matt Augustson | Lifecore Biomedical | N/A | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| Gene Esq | Shuttle Pharmaceuticals | N/A | |
| John Poggetto | Sonoma Pharmaceuticals | 52 | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Kara Morley | Lifecore Biomedical | N/A | |
| BA MA | Akanda Corp | 74 | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Brikkelle Thompson | Lifecore Biomedical | N/A | |
| Timothy CPA | Shuttle Pharmaceuticals | 66 | |
| Alycia Torres | Biofrontera | N/A | |
| Jon MBA | Biofrontera | N/A | |
| Daniel JD | Biofrontera | N/A | |
| Jerome Dvonch | Sonoma Pharmaceuticals | 56 | |
| Samantha Widdicombe | Biofrontera | N/A | |
| John Shulman | Petros Pharmaceuticals | 61 | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.18 |
China Pharma Holdings Management Team
Elected by the shareholders, the China Pharma's board of directors comprises two types of representatives: China Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of China. The board's role is to monitor China Pharma's management team and ensure that shareholders' interests are well served. China Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, China Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
China Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is China Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.70) % | ||||
| Operating Margin | (1.50) % | ||||
| Current Valuation | 8.8 M | ||||
| Shares Outstanding | 19.25 M | ||||
| Shares Owned By Insiders | 51.27 % | ||||
| Shares Owned By Institutions | 0.21 % | ||||
| Number Of Shares Shorted | 93.6 K | ||||
| Price To Earning | (0.89) X |
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.